Answers are grounded in this paper and cite their sources.
The present study aims to identify the potential role of circulating lymphocytic subpopulations as biomarkers for response to anti-PD-1 immunotherapy. Twenty-one cancer patients who were about to start treatment with either nivolumab or pembrolizumab and eight healthy donors were enrolled. Peripheral blood mononuclear cells were obtained for flow cytometric analysis at five consecutive time points up to six months. Total CD4+lymphocytes were significantly decreased, whereas T helper 17 and regulatory T lymphocytes were significantly increased within non-responders compared to healthy donors at treatment onset, indicating their potential significance for predicting non-response to CPI immunotherapy. However, further validation is required.
No takes yet. Share an insight, caveat, or question.
Salamaliki et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: